Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0FPQOM)
| ADC Name |
Emiltatug ledadotin
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
emiltatug ledadotin; XMT-1660; Emi-Le
Click to Show/Hide
|
|||||
| Organization |
Mersana Therapeutics (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
6
|
|||||
| Structure |
|
|||||
| Antibody Name |
Emiltatug
|
Antibody Info | ||||
| Antigen Name |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1)
|
Antigen Info | ||||
| Payload Name |
AF-HPA
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
A cleavable ester linker
|
Linker Info | ||||
| Conjugate Type |
Enzymatic Catalysis
|
|||||
| Combination Type |
ledadotin
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Peritoneal cancer | ||||
| Breast cancer | ||||
| Ovarian cancer | ||||
| Fallopian tube cancer | ||||
| Endometrial cancer | ||||
| Unspecific solid tumor |
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients (ECOG 0-1) have recurrent/advanced solid tumors (measurable per RECIST 1.1) and available tumor tissue. Key exclusions: prior auristatin-ADC treatment, untreated CNS metastases, active liver disease (cirrhosis/varices), uncontrolled systemic illness, or recent anticancer therapy/surgery (within specified washout periods). Brain MRI is required for TNBC or symptomatic/metastatic CNS history.
Click to Show/Hide
|
||||
| Administration Dosage |
XMT-1660 will be administered through a vein in your arm or port catheter (intravenously)
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05377996 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors | ||||
| Primary Endpoint |
The Phase 1 study evaluates DLTs within the first treatment cycle (17 months) to establish MTD/RP2D for XMT-1660, with safety/tolerability assessed via AEs over 3 years. Phase 2 expansion measures ORR per RECIST 1.1 (investigator-assessed CR/PR rates).
|
||||
| Other Endpoint |
Secondary endpoints include ORR (dose escalation), DOR (time to progression/death), and comprehensive PK analysis (Tmax, Cmax, AUC, clearance, half-life, volume of distribution, Ctrough) over 3 years. Immunogenicity (ADA/nAb development) is monitored throughout both phases.
|
||||